Nkarta said Monday that two experimental, off-the-shelf treatments, both made from engineered natural killer cells, induced complete responses in patients with advanced forms of blood cancer. The results marked the first reveal of clinical data from its research programs. In one of the clinical trials, three of five patients with acute myeloid leukemia achieved complete remissions. Two of those patients showed no evidence of residual disease — the best response possible following treatment with the highest-tested dose of the Nkarta engineered natural killer, or NK, cells.